References

  1. Stewart AF. Hypercalcemia associated with cancer. N Engl J Med. 2005;352(4):373-379.
  2. National Cancer Institute.Hypercalcemia PDQ. http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/HealthProfessional/page2. Updated January 9, 2008. Accessed February 10, 2008.
  3. Cvitkovic F, Armand J-P, Tubiana-Hulin M, et al. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cancer J. 2006;12(1):47-53.
  4. Van Poznak C. Hypercalcemia of malignancy remains a clinically relevant problem. Cancer J. 2006;12(1):21-23.
  5. Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT. Cancer-associated hypercalcemia: morbidity and mortality. Ann Intern Med. 1990;112(7):499-504.
  6. Mundy GR and Edwards JR. PTH-related peptide (PTHrP) in hypercalcemia. J Am Soc Nephrol. 2008. Epub ahead of print.
  7. Mundy GR. Incidence and pathophysiology of hypercalcemia. Calcif Tissue Int. 1990;46 (suppl):S3-S10.
  8. Inzucchi SE. Understanding hypercalcemia. Its metabolic basis, signs, and symptoms. Postgrad Med. 2004;115(4):69-76.
  9. Skugor M, Milas M. Hypercalcemia. http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/endocrinology/hcalcemia/hcalcemia..... Updated June 16, 2004. Accessed February 10, 2008.
  10. Oyajobi BO, Franchin G, Williams PJ, et al. Dual effects of macrophage inflammatory protein-1α on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood. 2003;102(1):311-319.
  11. Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston SR. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ. 2003;327(7413):469-476.
  12. Bell R. Efficacy of ibandronate in metastatic bone disease: review of clinical data. Oncologist. 2005;10(suppl 1):8-13.
  13. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19(2):558-567.
  14. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res. 2006;12(4):1221-1228.
  15. Oyajobi BO. Multiple myeloma/hypercalcemia. Arthritis Res Ther. 2007;9(suppl 1):S4.
  16. Morony S, Warmington K, Adamu S, et al. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology. 2005;146(8):3235-3234.
  17. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100(12):2613-2621.

 
 
 
 

  • 370 reads
 0